Formic Acid

Formic Acid

SCHEMBL2968613

CN(C)CCN(C)C.O=CO

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.47
CA2 P00918 1/20 0.47
CA3 P07451 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA5A P35218 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
CA5B Q9Y2D0 1/20 0.47
MAPT P10636 1/20 0.44
ALDH1A1 P00352 3/20 0.39
TSHR P16473 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRM3 P20309 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimethylaminoethanol SCHEMBL1132205 0.84
Formic Acid SCHEMBL3409907 0.84
Formic Acid SCHEMBL17184059 0.82 DNM1 (0.38) CA12CA2CA3CA4CA6
Formic Acid SCHEMBL2962390 0.82 CA12 (0.52) CA12CA2CA3CA4CA6
Formic Acid SCHEMBL27230851 0.82 CA12 (0.33) CA12CA2CA3CA4CA6
Formic Acid SCHEMBL2960819 0.80 CA12 (0.47) CA12CA2CA9MAPTALDH1A1
Formic Acid SCHEMBL2170935 0.80 DNM1 (0.55) CA12CA9MAPTALDH1A1TSHR
Formic Acid SCHEMBL5026932 0.80 MAPT (0.48) MAPTALDH1A1TSHRTDP1PAOX
N,N-Dimethylethanaminium SCHEMBL3414115 0.79
Formic Acid SCHEMBL17184057 0.78 TDP1 (0.54) MAPTALDH1A1TSHRTDP1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722753-B2 Hydroxyl terminated precursor and method of making the same LEAR CORPORATION (US) 2014-05-13 US disclosed
US-20100160593-A1 ISOCYANATO TERMINATED PRECURSOR AND METHOD OF MAKING THE SAME LEAR CORPORATION (US) 2010-06-24 US disclosed
US-7678936-B2 Isocyanato terminated precursor and method of making the same LEAR CORPORATION (US) 2010-03-16 US disclosed
WO-2009026426-A1 ISOCYANATO TERMINATED PRECURSOR AND METHOD OF MAKING THE SAME RENOSOL SYSTEMS, LLC (US) 2009-02-26 WO disclosed
US-20090054611-A1 HYDROXYL TERMINATED PRECURSOR AND METHOD OF MAKING THE SAME LEAR CORPORATION 2009-02-26 US disclosed
US-20090054604-A1 ISOCYANATO TERMINATED PRECURSOR AND METHOD OF MAKING THE SAME LEAR CORPORATION 2009-02-26 US disclosed
WO-2009026424-A1 HYDROXYL TERMINATED PRECURSOR AND METHOD OF MAKING THE SAME RENOSOL SYSTEMS, LLC (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054604-A1 ISOCYANATO TERMINATED PRECURSOR AND METHOD OF MAKING THE SAME IDH3A, IDH2, CBR3 CA12 162/4885CA2 471/4885CA3 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.